Text Size

Tipranavir Expanded Access Program (EAP)

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00097799
First received: November 30, 2004
Last updated: June 25, 2012
Last verified: June 2012
History of Changes
  Purpose

This study was designed to allow for access to tipranavir prior to FDA approval to treat drug resistant HIV infection.


Condition Intervention
HIV Infections
 Drug: Tipranavir
Drug: Ritonavir

Study Type: Expanded Access     What is Expanded Access?
Official Title: TPV Expanded Access Program in the United States

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Study Start Date: December 2004
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Tipranavir
    500 mg twice daily
    Drug: Ritonavir
    200 mg twice daily
  Eligibility

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00097799

  Show 115 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00097799     History of Changes
Other Study ID Numbers: 1182.70
Study First Received: November 30, 2004
Last Updated: June 25, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Ritonavir
 Tipranavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013